These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 1995956)

  • 1. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
    Connors M; Collins PL; Firestone CY; Murphy BR
    J Virol; 1991 Mar; 65(3):1634-7. PubMed ID: 1995956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cytolytic activity of pulmonary CD8+ lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice.
    Kulkarni AB; Connors M; Firestone CY; Morse HC; Murphy BR
    J Virol; 1993 Feb; 67(2):1044-9. PubMed ID: 8419638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.
    Kulkarni AB; Morse HC; Bennink JR; Yewdell JW; Murphy BR
    J Virol; 1993 Jul; 67(7):4086-92. PubMed ID: 7685408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
    Kulkarni AB; Collins PL; Bacik I; Yewdell JW; Bennink JR; Crowe JE; Murphy BR
    J Virol; 1995 Feb; 69(2):1261-4. PubMed ID: 7815502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
    Schmidt AC; Wenzke DR; McAuliffe JM; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 2002 Feb; 76(3):1089-99. PubMed ID: 11773385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication.
    Nicholas JA; Rubino KL; Levely ME; Meyer AL; Collins PL
    Virology; 1991 Jun; 182(2):664-72. PubMed ID: 2024493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
    Johnson PR; Olmsted RA; Prince GA; Murphy BR; Alling DW; Walsh EE; Collins PL
    J Virol; 1987 Oct; 61(10):3163-6. PubMed ID: 3305988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions.
    Taylor G; Thomas LH; Furze JM; Cook RS; Wyld SG; Lerch R; Hardy R; Wertz GW
    J Gen Virol; 1997 Dec; 78 ( Pt 12)():3195-206. PubMed ID: 9400970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
    Collins PL; Purcell RH; London WT; Lawrence LA; Chanock RM; Murphy BR
    Vaccine; 1990 Apr; 8(2):164-8. PubMed ID: 2336876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.
    Elango N; Prince GA; Murphy BR; Venkatesan S; Chanock RM; Moss B
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1906-10. PubMed ID: 3513191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein.
    Bembridge GP; Garcia-Beato R; López JA; Melero JA; Taylor G
    J Immunol; 1998 Sep; 161(5):2473-80. PubMed ID: 9725246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytolytic T-lymphocyte responses to respiratory syncytial virus: effector cell phenotype and target proteins.
    Nicholas JA; Rubino KL; Levely ME; Adams EG; Collins PL
    J Virol; 1990 Sep; 64(9):4232-41. PubMed ID: 2117070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon.
    Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G
    J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses.
    Takao SI; Kiyotani K; Sakaguchi T; Fujii Y; Seno M; Yoshida T
    J Virol; 1997 Jan; 71(1):832-8. PubMed ID: 8985426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.
    Openshaw PJ; Anderson K; Wertz GW; Askonas BA
    J Virol; 1990 Apr; 64(4):1683-9. PubMed ID: 2319650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.